Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.
Michael E. Hurwitz(Yale University), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States)), I. Gergel(Nektar Therapeutics (United States)), Adi Diab(Cleveland Clinic), Ute Hoch(University of Arizona), Michael J. Imperiale(University of Michigan), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Mary Tagliaferri(Nektar Therapeutics (United States)), Patrick Hwu(Moffitt Cancer Center), Harriet M. Kluger(Yale Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Mario Sznol(Yale University)
Cited by 3
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k